ASX:STK
ASX:STKMetals and Mining

3 ASX Penny Stocks With Market Caps Reaching A$900M

The Australian stock market has faced challenges recently, with the ASX200 underperforming compared to its global peers despite a US Fed Rate Cut. In such conditions, investors often look towards penny stocks as a potential avenue for growth. Although the term "penny stocks" may seem outdated, these smaller or newer companies can offer opportunities when they possess strong financials and clear growth prospects.
ASX:ILU
ASX:ILUMetals and Mining

Iluka Resources (ASX:ILU): Valuation Check After Withdrawing 2025 Synthetic Rutile Production Guidance

Iluka Resources (ASX:ILU) has been back in the spotlight after scrapping its 2025 synthetic rutile production guidance. The company cited an unresolved contract with a key UK customer that rattled investors and amplified recent downgrades. See our latest analysis for Iluka Resources. The guidance withdrawal has accelerated a pullback that was already forming, with a 7 day share price return of minus 8.87 percent and a 30 day share price return of minus 11.94 percent. However, the year to date...
ASX:BFG
ASX:BFGCapital Markets

ASX Penny Stocks To Consider In December 2025

As the Australian market experiences a mixed performance with materials leading and IT and industrials lagging, investors are keenly observing sector shifts. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.
ASX:ILU
ASX:ILUMetals and Mining

Iluka Resources (ASX:ILU) Is Down 8.9% After Pulling 2025 Synthetic Rutile Guidance Over Customer Uncertainty

In recent days, Iluka Resources withdrew its 2025 synthetic rutile production guidance due to uncertainty over a key UK customer agreement, prompting analyst downgrades and highlighting ongoing operational and market disruptions affecting its mineral sands and rare earths business. This shift draws attention to how sensitive Iluka’s outlook is to individual customer contracts, production reliability, and evolving tariffs and export controls in its core markets. We’ll now examine how the...
ASX:IMM
ASX:IMMBiotechs

Immutep (ASX:IMM): Valuation Check After Dr. Reddy’s Licensing Deal and New Phase II Breast Cancer Data

Immutep (ASX:IMM) has jumped onto investors radar after two meaningful updates: a lucrative licensing deal with Dr. Reddy’s for its cancer immunotherapy efti, and fresh Phase II breast cancer data reinforcing its development pathway. See our latest analysis for Immutep. The recent licensing deal and upbeat breast cancer data appear to have flipped sentiment, with a 1 month share price return of 25.49 percent and a 90 day share price return of 36.17 percent standing in contrast to a still...